Robert Harrington to Thrombosis
This is a "connection" page, showing publications Robert Harrington has written about Thrombosis.
Connection Strength
1.536
-
Cardiology patient page. Antiplatelet therapy. Circulation. 2003 Aug 19; 108(7):e45-7.
Score: 0.199
-
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circ Cardiovasc Interv. 2022 01; 15(1):e010390.
Score: 0.177
-
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. Int J Cardiol. 2019 Mar 01; 278:217-222.
Score: 0.143
-
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. Circ Cardiovasc Interv. 2016 May; 9(5):e003114.
Score: 0.120
-
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014 Feb 25; 63(7):619-629.
Score: 0.101
-
Platelet inhibition with cangrelor during PCI. N Engl J Med. 2013 07 25; 369(4):393-4.
Score: 0.099
-
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke. 2013 Aug; 44(8):e95-6.
Score: 0.098
-
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May; 44(5):1477-9.
Score: 0.097
-
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 04; 368(14):1303-13.
Score: 0.096
-
Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. J Thromb Thrombolysis. 2012 Jul; 34(1):143-63.
Score: 0.092
-
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, S?o Paulo, Brazil. J Thromb Thrombolysis. 2011 Aug; 32(2):242-66.
Score: 0.086
-
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost. 2004 Dec; 92(6):1182-93.
Score: 0.054
-
Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes. Semin Thromb Hemost. 2004 Dec; 30(6):639-47.
Score: 0.054
-
Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs. 2003; 3(6):423-36.
Score: 0.048
-
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8.
Score: 0.030
-
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):336-46.
Score: 0.023
-
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21; 360(21):2176-90.
Score: 0.018